Recurrent High-grade Glioma
12
1
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
16.7%
2 terminated out of 12 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (12)
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
AsiDNA Children, Adolescents and Young Adults
A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation